Acadia Pharmaceuticals (ACAD) Accounts Payables (2010 - 2026)
Acadia Pharmaceuticals' quarterly Accounts Payables came in at $12.2 million in Q1 2026, down 32.32% year-on-year from $18.1 million in Q1 2025, and up 12.32% quarter-over-quarter from $10.9 million in Q4 2025.
Acadia Pharmaceuticals has reported Accounts Payables for 17 years, with the latest figure at $12.2 million in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables fell 32.32% year-over-year to $12.2 million; the trailing twelve-month figure through Mar 2026 stood at $12.2 million (down 32.32% YoY), and the FY2025 full-year result was $10.9 million, down 32.66% from the prior year.
- Accounts Payables for Q1 2026 stood at $12.2 million, up from $10.9 million in the prior quarter.
- The five-year high for Accounts Payables was $21.7 million in Q3 2025, with the low at $10.0 million in Q3 2022.
- Average Accounts Payables over 5 years is $15.8 million, with a median of $17.4 million recorded in 2023.
- Year-over-year, Accounts Payables soared 85.37% in 2022 and plunged 32.66% in 2025.
- Tracing ACAD's Accounts Payables over 5 years: stood at $12.7 million in 2022, then jumped by 37.64% to $17.5 million in 2023, then slipped by 7.7% to $16.2 million in 2024, then slumped by 32.66% to $10.9 million in 2025, then increased by 12.32% to $12.2 million in 2026.
- The last three Accounts Payables figures came in at $12.2 million (Q1 2026), $10.9 million (Q4 2025), and $21.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Acadia Pharmaceuticals | 3.69 Bn | 2.84 Bn | 243.27 Mn | 12.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.25 Mn |
| Dec 31, 2025 | 10.90 Mn |
| Sep 30, 2025 | 21.75 Mn |
| Jun 30, 2025 | 20.10 Mn |
| Mar 31, 2025 | 18.10 Mn |
| Dec 31, 2024 | 16.19 Mn |
| Sep 30, 2024 | 19.08 Mn |
| Jun 30, 2024 | 19.88 Mn |
| Mar 31, 2024 | 19.33 Mn |
| Dec 31, 2023 | 17.54 Mn |
| Sep 30, 2023 | 12.31 Mn |
| Jun 30, 2023 | 18.81 Mn |
| Mar 31, 2023 | 17.42 Mn |
| Dec 31, 2022 | 12.75 Mn |
| Sep 30, 2022 | 10.01 Mn |
| Jun 30, 2022 | 11.85 Mn |
| Mar 31, 2022 | 10.77 Mn |
| Dec 31, 2021 | 6.88 Mn |
| Sep 30, 2021 | 7.72 Mn |
| Jun 30, 2021 | 9.07 Mn |
| Mar 31, 2021 | 8.85 Mn |
| Dec 31, 2020 | 8.49 Mn |
| Sep 30, 2020 | 3.47 Mn |
| Jun 30, 2020 | 6.47 Mn |
| Mar 31, 2020 | 6.62 Mn |
| Dec 31, 2019 | 7.22 Mn |
| Sep 30, 2019 | 3.44 Mn |
| Jun 30, 2019 | 4.65 Mn |
| Mar 31, 2019 | 3.28 Mn |
| Dec 31, 2018 | 3.17 Mn |
| Sep 30, 2018 | 2.96 Mn |
| Jun 30, 2018 | 3.33 Mn |
| Mar 31, 2018 | 3.00 Mn |
| Dec 31, 2017 | 8.79 Mn |
| Sep 30, 2017 | 2.96 Mn |
| Jun 30, 2017 | 3.59 Mn |
| Mar 31, 2017 | 2.17 Mn |
| Dec 31, 2016 | 3.91 Mn |
| Sep 30, 2016 | 2.83 Mn |
| Jun 30, 2016 | 1.02 Mn |
| Mar 31, 2016 | 1.31 Mn |
| Dec 31, 2015 | 1.67 Mn |
| Sep 30, 2015 | 2.20 Mn |
| Jun 30, 2015 | 2.92 Mn |
| Mar 31, 2015 | 2.52 Mn |
| Dec 31, 2014 | 2.02 Mn |
| Sep 30, 2014 | 1.11 Mn |
| Jun 30, 2014 | 1.10 Mn |
| Mar 31, 2014 | 1.56 Mn |
| Dec 31, 2013 | 372,000.00 |
| Sep 30, 2013 | 1.12 Mn |
| Jun 30, 2013 | 1.18 Mn |
| Mar 31, 2013 | 1.40 Mn |
| Dec 31, 2012 | 1.38 Mn |
| Sep 30, 2012 | 1.13 Mn |
| Jun 30, 2012 | 757,000.00 |
| Mar 31, 2012 | 1.04 Mn |
| Dec 31, 2011 | 1.96 Mn |
| Sep 30, 2011 | 1.26 Mn |
| Jun 30, 2011 | 1.14 Mn |
| Dec 31, 2010 | 1.97 Mn |